Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Deferred Taxes (2020 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Deferred Taxes for 5 consecutive years, with $48.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Deferred Taxes rose 253.99% year-over-year to $48.2 million, compared with a TTM value of $165.4 million through Dec 2025, up 234.36%, and an annual FY2025 reading of $165.4 million, up 234.36% over the prior year.
  • Deferred Taxes was $48.2 million for Q4 2025 at Neurocrine Biosciences, down from $168.3 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $168.3 million in Q3 2025 and bottomed at -$41.5 million in Q2 2023.
  • Average Deferred Taxes over 4 years is -$1.6 million, with a median of -$15.6 million recorded in 2024.
  • The sharpest move saw Deferred Taxes tumbled 730.95% in 2024, then skyrocketed 582.23% in 2025.
  • Year by year, Deferred Taxes stood at -$6.2 million in 2021, then skyrocketed by 432.26% to $20.6 million in 2023, then crashed by 251.94% to -$31.3 million in 2024, then surged by 253.99% to $48.2 million in 2025.
  • Business Quant data shows Deferred Taxes for NBIX at $48.2 million in Q4 2025, $168.3 million in Q3 2025, and -$37.4 million in Q2 2025.